Commentary|Articles|September 8, 2026

Beyond anti-VEGF: A multi-mechanism TKI approach to DME

Author(s)Kassi Filkins, Dante Pieramici, MD

Dante Pieramici, MD, discusses the phase 3 COMO and CAPRI trials of EYP-1901 in diabetic macular edema and what 6-month dosing could mean for treatment burden.

Extended-release drug delivery is reshaping the treatment landscape for retinal vascular disease, offering a potential answer to the persistent gap between the efficacy of anti-VEGF therapy in clinical trials and the undertreatment many patients experience in the real world.